💪 Build muscle & strength

What actually decides this outcome, in order of size

Hypertrophy is protein synthesis exceeding breakdown for long enough. Ranked by how much of the outcome each input owns, with the one number that puts the whole shelf in proportion at the top:

1. The training stimulus, which none of the 90-odd items here replaces. Mechanical tension activates mTORC1 through mechanisms partly independent of growth factor signaling, and it is the only input that is both necessary and sufficient to start the process. Everything on the 6 pathways below modifies the response to a stimulus that has to exist.
2. Androgen receptor signaling, and the size of it. Graded testosterone doses in 61 healthy young men produced fat-free mass changes of +3.4, +5.2 and +7.9 kg at the higher doses, correlating with log testosterone concentration at r=0.73 (P=0.0001) Bhasin 2001. That is the ceiling on this entire goal, produced pharmacologically over 20 weeks, and every botanical on the androgen pathway is arguing for a small percentage move inside a normal range.
3. Total protein intake, where the supplement's contribution is bounded in kg of lean mass. The systematic review and meta-regression of protein supplementation against resistance training found the benefit real and limited, and limited specifically by habitual intake Morton 2018. Below the plateau a 25 g shake is useful; above it, it is food.
4. Phosphocreatine availability, which is a compartment measured in mmol/kg rather than a signal. Six days at 20 g/day raises muscle total creatine by roughly 20%, and 2 to 3 g/day maintains it Hultman 1996; the position stand covering safety and efficacy supports habitual intake at that level Kreider 2017. A compartment already at 150 mmol/kg cannot be filled further, which is what a non-responder is.
5. Recovery capacity, which sets how much stimulus can be absorbed per 7 days. A program that outruns recovery is catabolic regardless of what is being taken alongside it, and the largest growth hormone pulse of the day is tied to slow-wave sleep. That is why Recovery, sleep & the anabolic window between sessions is a pathway rather than a footnote.

The order to run these in, and what has to be true first

Stimulus, then substrate, then the compartment, then the endocrine arguments. Reversing that is how somebody spends four figures on the sixth-ranked lever.

1. Fix the program and the protein total before any purchase. Progressive overload with enough weekly volume, and a daily protein target reached from food first. Only then does Whey Protein (RecoveryPro) or Essential Amino Acids become a way of closing a measured gap Morton 2018. Substrate, cell volume & training capacity is the pathway with the strongest evidence base on this hub by a wide margin, and it is the one people skip.
2. Creatine second, because it is the only supplement here whose mechanism is a filled compartment. Monohydrate at 3 to 5 g/day is what every trial used; the loading phase compresses saturation from about four weeks into about six days and changes nothing about the endpoint Hultman 1996 Kreider 2017.
3. Then the performance layer, which buys training quality rather than tissue. Beta-Alanine raises muscle carnosine, which buffers hydrogen ions during high-intensity work; the paresthesia is a dose-related effect of the bolus and is avoided by splitting it. Citrulline Malate raises plasma arginine more effectively than arginine does because it escapes intestinal and hepatic arginase, and HMB is a leucine metabolite with an anti-catabolic argument that is strongest in untrained and detrained states.
4. Then the endocrine pathways, in descending order of evidence. Androgen & anabolic-receptor signaling is the one with the dose-response data Bhasin 2001, and Enclomiphene belongs there only where the axis is genuinely suppressed. GH / IGF-1 axis is next, and the pathway's own why line is the honest one: growth hormone is excellent for connective tissue and body composition and is a weaker direct hypertrophic agent than its reputation.
5. HGH, Ipamorelin and MK-677 are three different things sold as one. Growth hormone itself is exogenous replacement; ipamorelin is a selective GH secretagogue receptor agonist that preserves the pulsatile pattern; MK-677 is an orally active secretagogue with a long half-life that raises IGF-1 continuously, which is a different physiology from a pulse and is why appetite and fluid retention behave differently on it.
6. Follistatin 344 and Turkesterone are the two most over-promised items on the hub. Myostatin inhibition is the most mechanistically compelling target in the field and the one where delivery has repeatedly defeated good biology, which is Myostatin & activin inhibition. Ecdysteroid claims rest on rodent and in vitro work plus a small number of human trials, and product analyses have repeatedly found less of the labeled compound than the label states.
7. BPC-157 (inj/oral) sits here for the injury half. Training capacity lost to an injury is training capacity lost to hypertrophy, which is why Satellite cells & local repair and Angiogenesis & cytoprotection are on the same problem from two directions.

What gets bought for this that cannot move it

More protein past the plateau is the commonest wasted spend on this hub. The meta-regression's central finding is that the increment from supplementation shrinks as habitual intake rises Morton 2018. A fourth shake in a day that already meets the target is an expensive carbohydrate-free snack, and the money buys more hypertrophy as food, sleep or an extra session.

Growth hormone's reputation was built on a change that is substantially water. GH promotes sodium retention through the renal tubule and raises extracellular fluid, and it raises intramuscular glycogen storage, both of which produce a rapid and visible change in the mirror and on the scale. Against the androgen dose-response, where fat-free mass tracked the hormone concentration across the whole range Bhasin 2001, the direct hypertrophic effect of GH in adults with a normal axis is small.

The category that fails structurally is anything asked to work without a stimulus. Anabolic signaling raises the ceiling on a response that training initiates; with no training there is no response to amplify, only the side effects. That is why every honest ranking on this hub puts the program first and why a supplement stack taken through a deload does nothing.

And if the actual goal is a smaller waist rather than a bigger arm, this is the wrong hub. Muscle gain and fat loss are opposite energy states and running them together produces a slow version of both, which is Lean-mass protection while cutting. If the reason for coming here is strength that has stopped responding despite everything above, the questions are recovery and the axis: Sleep depth, slow-wave & recovery quality and Upstream stimulation — keeping the axis running.

How you would know it was working, on a real read-out and a real timescale

This is a goal with an unusually honest read-out, because the performance measure is more sensitive than the blood work. The prediction: strength on a fixed lift moves at 6 to 8 weeks and body composition at 12 to 16, and if a compound is doing something the strength number moves before the mirror does.

• A fixed lift, at a fixed repetition target, logged every session. This is the primary end point and it is free. Twelve weeks of logged sessions distinguishes a real effect from a good month in a way no photograph does.
• Body mass at 7 days when creatine starts. Creatine is osmotically active and intracellular, so 0.5 to 1.5 kg in week one on a loading protocol is water into muscle. Nothing moving over six weeks with no strength change is a full compartment rather than a failed product.
• Total Testosterone with Free Testosterone and SHBG (Sex Hormone-Binding Globulin) only if there is a reason. Measuring a normal axis to optimize it is the trap; measuring a suppressed one to decide whether the endocrine pathways apply is the use. Morning, twice.
• IGF-1 (Insulin-like Growth Factor 1) at 6 weeks if a secretagogue is being used, and read it as a pharmacodynamic marker rather than as an outcome. IGF-1 is produced hepatically in response to GH and integrates over days rather than tracking pulses, which is exactly why it is the right marker for whether a secretagogue is working and the wrong one for whether muscle is being built.
• Complete Blood Count (CBC) with Differential and Comprehensive Metabolic Panel (CMP) at 12 weeks on anything hormonal. Hematocrit rises on androgens and is the commonest reason a protocol has to change; creatinine rises on creatine without any change in filtration, which is why Cystatin C with eGFR resolves that particular argument. Grip strength annually is worth recording for a reason that has nothing to do with the gym Celis-Morales 2018.

What will fool you. The first six weeks of any new program are dominated by neural adaptation, so strength rises steeply while muscle cross-sectional area barely changes, and whatever was started that week gets the credit. Water shifts from creatine, carbohydrate loading and sodium move the scale by more than a fortnight of hypertrophy does. And starting a program and a stack in the same week means the stack is untestable for a year.

Sources read for these sections

• Bhasin S. Testosterone dose-response relationships in healthy young men. American Journal of Physiology Endocrinology and Metabolism 2001;281(6):E1172-81 · PMID 11701431
• Morton RW. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine 2018;52(6):376-384 · PMID 28698222
• Kreider RB, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition, 2017 · PMID 28615996
• Hultman E, et al. Muscle creatine loading in men. Journal of Applied Physiology, 1996 · PMID 8828669
• Celis-Morales CA. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ 2018;361:k1651 · PMID 29739772